지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
초록· 키워드
오류제보하기
Ulcerative colitis (UC) is characterized by a life-long chronic course with remissions and exacerbations. Use of biological therapies may reduce or delay the surgical procedures in patients with UC. The aim of this study was to determine the impact of infliximab (IFX) use on the rate of remission, surgical interventions, and the effect on quality of life in patients with moderate to severe UC. Literature was searched for studies that investigated the efficacy of IFX on the rate of remission, colectomy and quality of life (QoL) between January 1990 and June 2012 at MEDLINE, January 1988 and June 2012 at EMbase and others. Eleven trials were included in the meta-analysis; divided into placebo controlled 8 trials and intravenous corticosteroid controlled group 3 trials. In comparison to placebo control groups, patients who received IFX had an odds ratio (OR) of 3.712 (95% CI: 2.714, 5.079) for the short-term clinical remission, and 3.053(95% CI: 2.044, 4.559) for the rate of long-term remission. In colectomy rate and quality of life (QoL), odds ratio were 0.566(95% CI: 0.387, 0.827) and 0.658 (0.505, 0.811) respectively. Any adverse reactions including infections, infusion reaction, rash and arthralgia were equivalent in both groups. Compared with intravenous corticosteroid controlled group,patients who received IFX had lower remission rate with short-term odds ratio 0.227 (95% CI: 0.033, 1.556) and longterm odds ratio 1.054 (95% CI: 0.317, 3.502) respectively. However, statistical significance was not showed with both two analyses. The higher adverse drug reaction (ADR) rates were occurred in the corticosteroid controlled groups. 73.3%of patients treated corticosteroid reported Cushing-like syndrome with moon face. In conclusion, IFX does increase remission rate and decrease the rate of colectomy in patients with UC without elevating any adverse reactions significantly.
IFX also improves QoL in moderate to severe UC patients. It would not exceed the efficacy of intravenous corticosteroid,whereas intravenous corticosteroid also reported high rate of adverse reactions
목차
등록된 정보가 없습니다.
참고문헌 (24)
참고문헌 신청
Arts J / 2004 / Long-term outcome of treatment with intravenous cyclosporine in patients with severe ulcerative colitis / Inflamm Bowel Dis 10 : 73 ~ 78
Hahnloser D / 2004 / The effect of aging on function and quality of life in ileal pouch patients: a single cohort experience of 409 patients with chronic ulcerative colitis
Hove T / 2002 / Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease / Gut 50 : 206 ~ 211
Jadad AR / 1996 / Assessing the quality of reports of randomized clinical trials: is bliniding necessary? / Control Clin Trials 17 : 1 ~
Jarnerot G / 1985 / Intensive intravenous treatment of ulcerative colitis / Gastroenterology 89 : 1005 ~ 1013
Hahnloser D / 2004 / The effect of aging on function and quality of life in ileal pouch patients: a single cohort experience of 409 patients with chronic ulcerative colitis
Hove T / 2002 / Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease / Gut 50 : 206 ~ 211
Jadad AR / 1996 / Assessing the quality of reports of randomized clinical trials: is bliniding necessary? / Control Clin Trials 17 : 1 ~
Jarnerot G / 1985 / Intensive intravenous treatment of ulcerative colitis / Gastroenterology 89 : 1005 ~ 1013
이 논문의 저자 정보
최근 본 자료
댓글(0)
0